We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
JAZZ's Zepzelca Combo SCLC Study Fails, Drug Still Promising
Read MoreHide Full Article
Jazz Pharmaceuticals plc (JAZZ - Free Report) and partner PharmaMar announced data from the phase III ATLANTIS study evaluating a combination regimen of their small cell lung cancer (SCLC) drug, Zepzelca (lurbinectedin). Although the study failed to meet its pre-specified criteria of significance for the primary endpoint of overall survival (OS), the company believes overall results support the activity and tolerability of the drug in metastatic SCLC.
The ATLANTIS study evaluated 2.0mg/m2 dose of Zepzelca in combination with doxorubicin versus physician's choice of topotecan or cyclophosphamide/doxorubicin/vincristine in adult SCLC patients whose disease progressed on or after platinum-based chemotherapy. Please note that Zepzelca received accelerated approval from the FDA as monotherapy for metastatic SCLC patients in similar setting earlier in June. We also note that the study evaluated a lower dose of the drug compared to 3.2mg/m2 FDA-approved dose. Moreover, the study did not evaluate Zepzelca monotherapy.
The safety profile in the ATLANTIS study was consistent with the known safety profile of Zepzelca monotherapy.
Detailed data from the study will be presented at a future medical meeting. Based on the ATLANTIS study data, Jazz plans further development of Zepzelca as monotherapy as well as in combination in SCLC and other tumors. The company will also provide the study data to the FDA and discuss with the regulatory body the confirmatory data needed for full approval of the drug as monotherapy.
Jazz entered into an exclusive license agreement with Spain-based Pharma Mar in December 2019, gaining U.S. commercialization rights to lurbinectedin. The company launched the drug in the U.S. market in July. The drug recorded sales of $36.9 million in the third quarter, representing promising launch uptake. The company had also raised its financial guidance for 2020 based on strong performance of its drugs during the third quarter and the robust launch of Zepzelca.
Several analysts are also of the view that failure to meet the primary endpoint in the ATLANTIS study is unlikely to affect Zepzelca’s accelerated approval and have minimal impact on the uptake trend for the drug as monotherapy.
Shares of Jazz were up almost 4.5% on Dec 3 following the announcement. The company’s shares have gained 36.9% since June end compared to the industry’s increase of 3.2% in the same time frame, staging a comeback after falling more than 25% in the first half of 2020.
Apart from Zepzelca, Jazz has two marketed cancer drugs in its portfolio — Erwinaze and Vyxeos. However, Jazz generates the majority of its revenues from its sleep franchise led by Xyrem. We note that the FDA approved Xywav, a low sodium formulation of Xyrem, in July 2020 for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy. The low sodium content of the same boosts its potential as it can cater to a greater number of patients compared to Xyrem.
Bellicum’s loss per share estimates have narrowed 73.8% for 2021 over the past 30 days.
Ironwood earnings estimates have been revised 23.7% higher for 2021 over the past 30 days.
Catalent’s earnings per share estimates have move up 5% for 2021 over the past 30 days. The stock has surged 66% year to date.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
JAZZ's Zepzelca Combo SCLC Study Fails, Drug Still Promising
Jazz Pharmaceuticals plc (JAZZ - Free Report) and partner PharmaMar announced data from the phase III ATLANTIS study evaluating a combination regimen of their small cell lung cancer (SCLC) drug, Zepzelca (lurbinectedin). Although the study failed to meet its pre-specified criteria of significance for the primary endpoint of overall survival (OS), the company believes overall results support the activity and tolerability of the drug in metastatic SCLC.
The ATLANTIS study evaluated 2.0mg/m2 dose of Zepzelca in combination with doxorubicin versus physician's choice of topotecan or cyclophosphamide/doxorubicin/vincristine in adult SCLC patients whose disease progressed on or after platinum-based chemotherapy. Please note that Zepzelca received accelerated approval from the FDA as monotherapy for metastatic SCLC patients in similar setting earlier in June. We also note that the study evaluated a lower dose of the drug compared to 3.2mg/m2 FDA-approved dose. Moreover, the study did not evaluate Zepzelca monotherapy.
The safety profile in the ATLANTIS study was consistent with the known safety profile of Zepzelca monotherapy.
Detailed data from the study will be presented at a future medical meeting. Based on the ATLANTIS study data, Jazz plans further development of Zepzelca as monotherapy as well as in combination in SCLC and other tumors. The company will also provide the study data to the FDA and discuss with the regulatory body the confirmatory data needed for full approval of the drug as monotherapy.
Jazz entered into an exclusive license agreement with Spain-based Pharma Mar in December 2019, gaining U.S. commercialization rights to lurbinectedin. The company launched the drug in the U.S. market in July. The drug recorded sales of $36.9 million in the third quarter, representing promising launch uptake. The company had also raised its financial guidance for 2020 based on strong performance of its drugs during the third quarter and the robust launch of Zepzelca.
Several analysts are also of the view that failure to meet the primary endpoint in the ATLANTIS study is unlikely to affect Zepzelca’s accelerated approval and have minimal impact on the uptake trend for the drug as monotherapy.
Shares of Jazz were up almost 4.5% on Dec 3 following the announcement. The company’s shares have gained 36.9% since June end compared to the industry’s increase of 3.2% in the same time frame, staging a comeback after falling more than 25% in the first half of 2020.
Apart from Zepzelca, Jazz has two marketed cancer drugs in its portfolio — Erwinaze and Vyxeos. However, Jazz generates the majority of its revenues from its sleep franchise led by Xyrem. We note that the FDA approved Xywav, a low sodium formulation of Xyrem, in July 2020 for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy. The low sodium content of the same boosts its potential as it can cater to a greater number of patients compared to Xyrem.
Jazz Pharmaceuticals PLC Price
Jazz Pharmaceuticals PLC price | Jazz Pharmaceuticals PLC Quote
Zacks Rank & Stocks to Consider
Jazz currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks worth considering in the same sector include Bellicum Pharmaceuticals , Ironwood Pharmaceuticals (IRWD - Free Report) and Catalent (CTLT - Free Report) , all carrying Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Bellicum’s loss per share estimates have narrowed 73.8% for 2021 over the past 30 days.
Ironwood earnings estimates have been revised 23.7% higher for 2021 over the past 30 days.
Catalent’s earnings per share estimates have move up 5% for 2021 over the past 30 days. The stock has surged 66% year to date.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>